Fundz
You are reading one round. Fundz also knows which of your own LinkedIn connections can open this account.See it live →

ImpriMed secures $10 million in a Series A2 bridge round, with NAVER D2SF as a key investor. This funding will help ImpriMed advance its AI-driven precision medicine solutions.

PRIVATESep 18, 2026•about 3 hours ago

Amount Raised

$10 Million

Round Type

Series A

Mountain ViewBiotechnologyHealth CareArtificial IntelligenceMedicalHealth Diagnostics

Investors

Naver D2 Sf

Description

NAVER D2SF has invested in ImpriMed, joining the company's $10 million Series A2 bridge round. ImpriMed focuses on AI-driven precision medicine, leveraging data to enhance personalized treatment decisions. The funding will support its efforts to commercialize products and establish partnerships in North America. ImpriMed aims for FDA clearance and CLIA certification by early 2027.

Company Information

Company

ImpriMed

Location

Mountain View, California, United States

About

ImpriMed provides cutting-edge personalized medicine easily accessible for pets with blood cancer diseases. ImpriMed’s key product, Personalized Prediction Profile, has been used by board-certified veterinary oncologists, helping over 4,000 dogs with lymphoma and leukemia. With ImpriMed’s services, veterinarians make their treatment decisions quickly and with confidence. This innovative approach to cancer care has been published in a scientific journal and presented at major conferences and is supported by over 200 veterinary oncologists at 80+ specialty hospitals in the US.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment ImpriMed raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for ImpriMed's next move

See what Strategic adds

Funding Insights

Based on industry data
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

ImpriMed raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.